Health  Vol.2 No.7 , July 2010
Influence of poloxamer 407 on fractional and subfractional composition of serum lipoproteins of mice
Abstract: Using a novel small-angle X-ray scattering (SAXS) method for determination of fractional and subfractional composition of lipoproteins (LPs), a significant elevation of total cholesterol-lipop- roteins (C-LP) and, especially, total triglyceride- lipoproteins (TG-LP), was shown in this work. Among the LP fractions, poloxamer 407 was shown to significantly increase proatherogenic total C-LDL, TG-LDL and, especially, their precursors C-VLDL and TG-VLDL, while only exhibiting a moderate increase in the antiatherogenic C-HDL and TG-HDL fractions. With regard to the VLDL subfractions, significant elevations were observed in both subfractions studied; namely, C-VLDL1-2 and C-VLDL3-5. Similar chang- es were noted in the TG-VLDL1-2 and TG- VLDL3-5 subfractions. The C-IDL and TG-IDL subfractions were increased significantly (?20- to 30- fold), while the C-LDL1-3 subfraction was moderately (?3- to 5-fold) increased at 48 hrs and at day 4. In the moderately elevated (?2- to 4-fold) anti-atherogenic HDL fraction, the C-HDL2 subfraction was increased more significantly (?4- fold) compared to the C-HDL3 subfraction; how- ever, both C-HDL subfractions returned to base- line by day 4. The elevation in the TG-HDL2 subfraction was observed only at 24 hrs. Mouse models of hyperlipidemia and atherosclerosis are useful to evaluate the role of “individual” LPs, as well as their fractions and subfractions, in hyperlipidemia and the genesis of atherosclerosis.
Cite this paper: nullKorolenko, T. , Tuzikov, F. , Johnston, T. , Tuzikova, N. , Filjushina, E. , Loginova, V. and Savchenko, N. (2010) Influence of poloxamer 407 on fractional and subfractional composition of serum lipoproteins of mice. Health, 2, 722-730. doi: 10.4236/health.2010.27110.

[1]   Anderson, L. (2005) Candidate-based proteomics in the search for biomarkers of cardiovascular disease, The Journal of Physiology, 563(1), 23-60.

[2]   Gotto, A.M, Jr, and Farmer, J.A. (2006) Drug insight: The role of statins in combination with ezetimide to lower LDL cholesterol. Nature Clinical Practice Cardiovascular Medicine, 3(12), 664-672.

[3]   Ugawa, T., Kakuta, H., Moritani, H., Inagaki, O. and Shikama, H. (2003) YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. British Journal of Pharmacology, 139(1), 140-146.

[4]   Tuzikov, F.V., Tuzikova, N.A., Galimov, R.V., Panin, L.E. and Nevinsky, G.A. (2002) General model to describe the structure and dynamic balance between different human serum lipoproteins and its practicl application. Medical Science Monitor, 8(6), pp. 79-88.

[5]   Dumortier, G., Grossiord, J.L., Agnely, F. and Chaumeil, J.C. (2006) A review of poloxamer 407 pharmaceutical and pharmacological Characteristics. Pharmaceuticals Research, 23(12), 2709-2728.

[6]   Leon, C., Wasan, K.M., Sachs-Barrable, K. and Johnston, T.P. (2006) Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharmaceuticals Research, 23(7), 1597-1607.

[7]   Kim, H.Y., Jeong, D.M., Jung, H.J., Jung, H.J., Yozokawa, T. and Choi, J.S. (2008) Hypolipidemic effects of Sophora Flavescens and its constituents in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Biological & Pharmaceutical Bulletin, 31(1), 73-78.

[8]   Johnston, T.P. and Palmer, W.K. (1997) The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy, 17(2), 342-347.

[9]   Johnston, T.P., Baker, J.C., Hall, D., Jamal, S., Palmer, W.K. and Emeson, E.E. (2000) Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis, 149(2), 303-313.

[10]   Johnston, T.P., Nguyen, L.B., Chu, W.A. and Shefer, S. (2001) Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. International Journal of Pharmaceutics, 229(1-2), 75-86.

[11]   Nash, V.J., Johnston, T.P. and Palmer, W.K. (1996) Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy, 16(1), 10-15.

[12]   Johnston, T.P., Li, Y., Jamal, A.S., Stechschulte, D.J. and Dileepan, K.N. (2003) Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages. Mediators of Inflammation, 12(3), 147- 155.

[13]   Johnston, T.P. (2009) Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1, and E-selectin, in C57BL/6 Mice. Journal of Pharmacy and Pharmacology, 61(12), 1681-1688.

[14]   Johnston, T.P. and Waxman, D.J. (2008) The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα. Journal of Pharmaceutical Sciences, 60(6), 753-759.

[15]   Otvos, J.D. (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clinical Laboratory, 48(3-4), 171-180.

[16]   Pelton, P.D, Patel, M. and Demarest, K.T. (2005) Nuclear receptors as potential targets for modulating reverse cholesterol transport, Current Topics in Medicinal Chemistry, 5(3), 265-282.

[17]   Jeyarajah, E.J., Cromwell, W.C. and Otvos, J.D. (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clinics in Laboratory Medicine, 26(4), 847-870.

[18]   Cromwell, W.C. and Otvos, J.D. (2006) Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. American Journal of Cardiology, 98(12), 1599-1602.

[19]   Bozóky, Z., Fül?p, L. and K?hidai, L. (2001) A short run new analytical ultracentrifugal micromethod for determining low-density lipoprotein sub-fractions using Sch- lieren refractometry. European Biophysics Journal, 29(8), 621-627.

[20]   Barcia, A.M. and Harris, H.W. (2005) Triglyceride-rich lipoproteins as agents of innate immunity, Clinical Infectious Diseases, 41(10), S498-503.

[21]   Tanaka, H., Ishida, T., Johnston, T.P., Yasuda, T., Ueyama, T., Kojima, Y., Kundu, R.K., Quertermous, T. and Hirata, K.-I. (2009) Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia. Journal of Atherosclerosis and Thrombosis, 16(4), 327-338.

[22]   Gatica, L.V., Vega, V.A., Zirulnik, F., Oliveros, L.B. and Gimenez, M.S. (2006) Alterations in the lipid metabolism of rat aorta: Effects of vitamin A deficiency. Journal of Vascular Research, 43(6), 602-610.

[23]   Brown, R.J. and Rader, D.J. (2007) Lipases as modulators of atherosclerosis in murine models. Current Drug Targets, 8(12), 1307-1319.

[24]   Ballabio, A. and Gieselmann, V. (2009) Lysosomal disorders: from storage to cellular damage. Biochimica et Biophysica Acta, 1793(4), 684-696.

[25]   Johnston, T.P. and Palmer, W.K. (1993) Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochemical Pharmacology, 46(6), 1037-1042.

[26]   Millar, J.S., Cromley, D.A, McCoy, M.G., Rader, D.J. and Billheimer, J.T. (2005) Determining hepatic triglyceride production in mice: Comparison of poloxamer 407 with triton WR 1339. Journal of Lipid Research, 46(9), 2023-2028.

[27]   Schneider, P., Korolenko, T.A. and Busch, U. (1997) A review of drug-induced lysosomal disorders of the liver in man and laboratory animals, Microscopy Research and Technique, 36(4), 253-275.

[28]   Johnston, T.P. (2004) The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: A review of findings to date. Journal of Cardiovascular Pharmacology, 43(4), 595-606.

[29]   Kuzman, D., Fon Tacer, K., Cerne, M., Rezen, T., Acimovic, J., Cegovnik, U., Kocjan, D., Urleb, U. and Rozman, D. (2009) Modulation of hepatic transcriptome in the poloxamer P-407 hyperlipidemia mouse model. Acta Chimica Slovenica, 56(1), 262-269.

[30]   Fruchart, J.C. and Duriez, P. (2006) Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc), 42(1), 39-64.

[31]   Butler, J.A., Hagen, T.M. and Moreau, R. (2009) Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Archives of Biochemistry and Biophysics, 485(1), 63-71.

[32]   Mora, S., Otvos, J.D., Rifai, N., Rosenson, R.S., Buring, J.E. and Ridker, P.M. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119(17), 931- 939.

[33]   Zhou, X., Johnston, T.P., Johansson, D., Parini, P., Funa, K., Svensson, J. and Hansson, G.K. (2009) Hypercholesterolemia leads to elevated TGF-beta 1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice, Atherosclerosis, 204(2), 381-387.

[34]   Gotto, A.M. and Farmer, J.A. (2007) Atherosclerosis: Pathogenesis, morphology, and risk factors. Willerson J.T., Wellens H., Cohn J.N. and Holmes D.R., Jr. Edition, Cardiovascular Medicine, 3rd Edition, Springer, London, pp. 1593-1613.